Life in the shadow of a dominant partner: The FVIII-VWF association and its clinical implications for hemophilia A

Blood

Volumn 128, Issue 16, 2016, Pages 2007-2016

  Pipe, Steven W ^a   Montgomery, Robert R ^b   Pratt, Kathleen P ^c   Lenting, Peter J ^d   Lillicrap, David ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

^c Uniformed Services University of the Health Sciences   (United States)

^d INSERM   (France)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; BLOOD CLOTTING FACTOR 8; C TYPE LECTIN DOMAIN FAMILY 4 MEMBER M; HEPARIN SULFATE PROTEOGLYCAN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PEPTIDES AND PROTEINS; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR CLASS A MEMBER 5; SIGLEC 5; STABILIN 2; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; F8 PROTEIN, HUMAN; HYBRID PROTEIN;

CLEARANCE; ENDOTHELIUM CELL; GLOMERULUS; GLYCOSYLATION; HALF LIFE TIME; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; LIVER CELL; LIVER SINUSOID; LYMPH VESSEL ENDOTHELIUM; MACROPHAGE; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; VASCULAR ENDOTHELIUM; BLOOD; METABOLISM;

FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HUMANS; RECOMBINANT FUSION PROTEINS; VON WILLEBRAND FACTOR;

EID: 84992390506     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-04-713289     Document Type: Review

References (129)

1. Do H, Healey JF, Waller E.K., Lollar P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem. 1999; 274(28): 19587-19592.
2. Jacquemin M, Neyrinck A, Hermanns M.I., et al. FVIII production by human lung microvascular endothelial cells. Blood. 2006; 108(2):515-517.
3. Schenone M, Furie BC, Furie B. The blood coagulation cascade. Curr Opin Hematol. 2004; 11(4):272-277.
4. Terraube V, O'Donnell JS, Jenkins PV Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia. 2010; 16(1):3-13.
5. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004; 104(5):1243-1252.
6. Schneppenheim R, Budde U. von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. J Thromb Haemost. 2011; 9(suppl 1): 209-215.
7. Rosner F. Hemophilia in the Talmud and rabbinic writings. Ann Intern Med. 1969; 70(4):833-837.
8. Lane S. Successful transfusion of blood. Lancet. 1840; 1:185-188.
9. Von Willebrand EA. Hereditary pseudohaemophilia. Haemophilia. 1999; 5(3): 223-231.
10. Barrow EM, Roberts HR, Pons K, Graham JB Studies of the antihemophilic factor (Ahf, factor Viii) produced in von Willebrand's disease. Proc Soc Exp Biol Med. 1964; 115: 760-763.
11. Switzer ME, McKee PA Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure. J Clin Invest. 1976; 57(4):925-937.
12. Zimmerman TS, Edgington TS Factor VIII coagulant activity and factor VIII-like antigen: independent molecular entities. J Exp Med. 1973; 138(4):1015-1020.
13. Michaux G, Cutler DF How to roll an endothelial cigar: the biogenesis of Weibel-Palade bodies. Traffic. 2004; 5(2):69-78.
14. Sporn LA, Chavin SI, Marder V.J., Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest. 1985; 76(3): 1102-1106.
15. Wagner DD, Olmsted JB, Marder VJ Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol. 1982; 95(1):355-360.
16. Ruggeri ZM, Zimmerman TS Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest. 1980; 65(6): 1318-1325.
17. Mannucci PM, Ruggeri ZM, Pareti F.I., Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1977; 1(8017):869-872.
18. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets. 2001; 12(5):261-273.
19. Kaplan KL, Owen J. Plasma levels of platelet secretory proteins. Crit Rev Oncol Hematol. 1986; 5(3):235-255.
20. Flood VH, Gill JC, Christopherson P.A., et al. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost. 2012; 10(7):1417-1424.
21. Ruggeri ZM, Orje JN, Habermann R, Federici A.B., Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood. 2006; 108(6): 1903-1910.
22. Coller BS, Peerschke EI, Scudder L.E., Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood. 1983; 61(1):99-110.
23. Ruggeri ZM, De Marco L, Gatti L, Bader R., Montgomery RR. Platelets have more than one binding site for von Willebrand factor. J Clin Invest. 1983; 72(1):1-12.
24. Schullek J, Jordan J, Montgomery RR Interaction of von Willebrand factor with human platelets in the plasma milieu. J Clin Invest. 1984; 73(2):421-428.
25. Bontempo FA, Lewis JH, Gorenc T.J., et al. Liver transplantation in hemophilia A. Blood. 1987; 69(6):1721-1724.
26. Marchioro TL, Hougie C, Ragde H., Epstein RB, Thomas ED. Hemophilia: role of organ homografts. Science. 1969; 163(3863):188-190.
27. Groth CG, Hathaway WE, Gustafsson A, et al Correction of coagulation in the hemophilic dog by transplantation of lymphatic tissue. Surgery. 1974; 75(5):725-733.
28. Norman JC, Covelli VH, Sise HS Transplantation of the spleen: experimental cure of hemophilia. Surgery. 1968; 64(1):1-14.
29. Lamont PA, Ragni MV Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation. J Thromb Haemost. 2005; 3(10):2259-2263.
30. Madeira CL, Layman ME, de Vera RE, Fontes PA, Ragni MV. Extrahepatic factor VIII production in transplant recipient of hemophilia donor liver. Blood. 2009; 113(21): 5364-5365.
31. Hollestelle MJ, Thinnes T, Crain K., et al. Tissue distribution of factor VIII gene expression in vivo-a closer look. Thromb Haemost. 2001; 86(3):855-861.
32. Everett LA, Cleuren AC, Khoriaty R.N., Ginsburg D. Murine coagulation factor VIII is synthesized in endothelial cells. Blood. 2014; 123(24): 3697-3705.
33. Fahs SA, Hille MT, Shi Q, Weiler H., Montgomery RR. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood. 2014; 123(24):3706-3713.
34. Shi Q, Fahs SA, Kuether E.L., Cooley BC, Weiler H, Montgomery RR. Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. Blood. 2010; 116(16): 3049-3057.
35. Turner NA, Moake JL Factor VIII is synthesized in human endothelial cells, packaged in Weibel-Palade bodies and secreted bound to ULVWF strings. PLoS One. 2015; 10(10):e0140740.
36. Pan J, Dinh TT, Rajaraman A, et al Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. Blood. 2016; 128(1):104-109.
37. Montgomery RR, Gill JC Interactions between von Willebrand factor and factor VIII: where did they first meet. J Pediatr Hematol Oncol. 2000; 22(3):269-275.
38. Rosenberg JB, Foster PA, Kaufman R.J., et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest. 1998; 101(3):613-624.
39. Montgomery RR, Hathaway WE, Johnson J, Jacobson L., Muntean W. A variant of von Willebrand's disease with abnormal expression of factor VIII procoagulant activity. Blood. 1982; 60(1):201-207.
40. Tuley EA, Gaucher C, Jorieux S., Worrall NK, Sadler JE, Mazurier C. Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci USA. 1991; 88(14):6377-6381.
41. Mazurier C, Gaucher C, Jorieux S., Goudemand M; Collaborative Group. Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Br J Haematol. 1994; 88(4):849-854.
42. van den Biggelaar M, Meijer AB, Voorberg J, Mertens K. Intracellular cotrafficking of factor VIII and von Willebrand factor type 2N variants to storage organelles. Blood. 2009; 113(13): 3102-3109.
43. Nathwani AC, Reiss UM, Tuddenham E.G., et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014; 371(21):1994-2004.
44. McIntosh J, Lenting PJ, Rosales C, et al Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 2013; 121(17):3335-3344.
45. Rosenberg JB, Greengard JS, Montgomery RR Genetic induction of a releasable pool of factor VIII in human endothelial cells. Arterioscler Thromb Vasc Biol. 2000; 20(12):2689-2695.
46. Matsui H, Shibata M, Brown B., et al. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells. 2007; 25(10):2660-2669.
47. Shi Q, Schroeder JA, Kuether E.L., Montgomery RR. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies. J Thromb Haemost. 2015; 13(7): 1301-1309.
48. Ngo JC, Huang M, Roth D.A., Furie BC, Furie B. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure. 2008; 16(4):597-606.
49. Pratt KP, Shen BW, Takeshima K, Davie E.W., Fujikawa K., Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature. 1999; 402(6760):439-442.
50. Shen BW, Spiegel PC, Chang C.H., et al. The tertiary structure and domain organization of coagulation factor VIII. Blood. 2008; 111(3): 1240-1247.
51. Wakabayashi H, Fay PJ Molecular orientation of factor VIIIa on the phospholipid membrane surface determined by fluorescence resonance energy transfer. Biochem J. 2013; 452(2): 293-301.
52. Stoilova-McPhie S., Lynch GC, Ludtke S, Pettitt BM Domain organization of membrane-bound factor VIII. Biopolymers. 2013; 99(7):448-459.
53. Yee A, Kretz CA Von Willebrand factor: form for function. Semin Thromb Hemost. 2014; 40(1): 17-27.
54. Liu ML, Shen BW, Nakaya S, et al Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood. 2000; 96(3):979-987.
55. Shiltagh N, Kirkpatrick J, Cabrita L.D., et al. Solution structure of the major factor VIII binding region on von Willebrand factor. Blood. 2014; 123(26):4143-4151.
56. Yee A, Oleskie AN, Dosey A.M., et al. Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII. Blood. 2015; 126(8):939-942.
57. Chiu PL, Bou-Assaf GM, Chhabra E.S., et al. Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry. Blood. 2015; 126(8): 935-938.
58. Leyte A, van Schijndel HB, Niehrs C, et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem. 1991; 266(2):740-746.
59. Nielsen PF, Bak S, Vandahl B. Characterization of tyrosine sulphation in rFVIII (turoctocog alfa) expressed in CHO and HEK-293 cells. Haemophilia. 2012; 18(5): e397-e398.
60. Kannicht C, Ramström M, Kohla G., et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res. 2013; 131(1):78-88.
61. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia. 1999; 5(3):145-154.
62. Scandella D. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Vox Sang. 1996; 70(suppl 1):9-14.
63. Kahle J, Orlowski A, Stichel D., et al. Epitope mapping via selection of anti-FVIII antibody-specific phage-presented peptide ligands that mimic the antibody binding sites. Thromb Haemost. 2015; 113(2):396-405.
64. Markovitz RC, Healey JF, Parker E.T., Meeks SL, Lollar P. The diversity of the immune response to the A2 domain of human factor VIII. Blood. 2013; 121(14):2785-2795.
65. Nguyen PC, Lewis KB, Ettinger R.A., et al. Highresolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance. Blood. 2014; 123(17):2732-2739.
66. Pratt KP. Inhibitory antibodies in hemophilia A. Curr Opin Hematol. 2012; 19(5):399-405.
67. Lin JC, Ettinger RA, Schuman J.T., et al. Six amino acid residues in a 1200 Å 2 interface mediate binding of factor VIII to an IgG4k inhibitory antibody. PLoS One. 2015; 10(1):e0116577.
68. Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia. 2010; 16(102):66-70.
69. Ghosh K, Shetty S. Immune response to FVIII in hemophilia A: an overview of risk factors. Clin Rev Allergy Immunol. 2009; 37(2):58-66.
70. Gouw SC, van der Bom JG, Ljung R, et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013; 368(3): 231-239.
71. Franchini M, Coppola A, Rocino A., et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost. 2013; 39(7):752-766.
72. Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia. 2006; 12(suppl 6):102-106.
73. Klukowska A, Szczepański T, Vdovin V., Knaub S, Jansen M, Liesner R. Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII, Nuwiq(®)) in children with severe haemophilia A: efficacy, safety and pharmacokinetics [published online ahead of print September 14, 2015]. Haemophilia.
74. Lissitchkov T, Hampton K, von Depka M, et al. Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®)) in adults with severe haemophilia A: efficacy and safety [published online ahead of print August 28, 2015]. Haemophilia.
75. Dasgupta S, Repessé Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007; 109(2):610-612.
76. Delignat S, Repessé Y, Navarrete AM, et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia. 2012; 18(2): 248-254.
77. Sorvillo N, Hartholt RB, Bloem E, et al von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII. Haematologica. 2016; 101(3): 309-318.
78. Gharagozlou S, Sharifian RA, Khoshnoodi J, et al Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains. Thromb Haemost. 2009; 101(5):834-839.
79. Meeks SL, Cox CL, Healey J.F., et al. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood. 2012; 120(12): 2512-2520.
80. Lin Y, Yang X, Chevrier M.C., et al. Relationships between factor VIII: Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia. 2004; 10(5):459-469.
81. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R., Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost. 2002; 88(2):221-229.
82. Goudemand J, Laurian Y, Calvez T. Risk of inhibitors in haemophilia and the type of factor replacement. Curr Opin Hematol. 2006; 13(5): 316-322.
83. Iorio A, Halimeh S, Holzhauer S., et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010; 8(6):1256-1265.
84. Goudemand J, Rothschild C, Demiguel V., et al; FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006; 107(1):46-51.
85. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007; 109(11):4693-4697.
86. Peyvandi F, Mannucci PM, Garagiola I, et al A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016; 374(21):2054-2064.
87. d'Oiron R., Pipe SW, Jacquemin M. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia. 2008; 14(suppl 3): 138-146.
88. James EA, Kwok WW, Ettinger R.A., Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost. 2007; 5(12):2399-2407.
89. James EA, van Haren SD, Ettinger RA, et al. T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost. 2011; 9(4):689-699.
90. Kim YC, Zhang AH, Su Y, et al Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood. 2015; 125(7): 1107-1115.
91. Scott DW, Pratt KP, Miao CH Progress toward inducing immunologic tolerance to factor VIII. Blood. 2013; 121(22):4449-4456.
92. Sabatino DE, Nichols TC, Merricks E, Bellinger D.A., Herzog RW, Monahan PE. Animal models of hemophilia. Prog Mol Biol Transl Sci. 2012; 105: 151-209.
93. Lei TC, Scott DW Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood. 2005; 105(12):4865-4870.
94. Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood. 2006; 108(1):107-115.
95. Matsui H, Shibata M, Brown B., et al. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp31 T regulatory cells. Blood. 2009; 114(3):677-685.
96. Di Paola J., Lethagen S, Gill J., et al. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery. Haemophilia. 2011; 17(5):752-758.
97. Canis K, McKinnon TA, Nowak A, et al Mapping the N-glycome of human von Willebrand factor. Biochem J. 2012; 447(2):217-228.
98. Canis K, McKinnon TA, Nowak A, et al The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost. 2010; 8(1):137-145.
99. Gornik O, Wagner J, Pucić M, Knezević A, Redzic I, Lauc G. Stability of N-glycan profiles in human plasma. Glycobiology. 2009; 19(12): 1547-1553.
100. Knezevic A, Gornik O, Polasek O., et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology. 2010; 20(8):959-969.
101. Grewal PK, Uchiyama S, Ditto D., et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008; 14(6): 648-655.
102. Ellies LG, Ditto D, Levy G.G., et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA. 2002; 99(15):10042-10047.
103. Pegon JN, Kurdi M, Casari C., et al. Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica. 2012; 97(12):1855-1863.
104. Smith NL, Chen MH, Dehghan A, et al; Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010; 121(12):1382-1392.
105. Rydz N, Swystun LL, Notley C, et al The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood. 2013; 121(26):5228-5237.
106. Lenting PJ, Neels JG, van den Berg BM, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem. 1999; 274(34): 23734-23739.
107. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland D.K., Sarafanov AG. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem. 1999; 274(53):37685-37692.
108. Rastegarlari G, Pegon JN, Casari C, et al Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood. 2012; 119(9): 2126-2134.
109. Morange PE, Tregouet DA, Frere C, et al Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol. 2005; 128(1):91-99.
110. Bovenschen N, Rijken DC, Havekes L.M., van Vlijmen BJ, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005; 3(6):1257-1265.
111. Yee A, Gildersleeve RD, Gu S, et al A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood. 2014; 124(3):445-452.
112. Tang L, Leong L, Sim D., et al. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. Haemophilia. 2013; 19(4): 539-545.
113. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7(9):715-725.
114. Mahlangu J, Powell JS, Ragni M.V., et al; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014; 123(3): 317-325.
115. Shapiro AD, Ragni MV, Kulkarni R, et al Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014; 12(11): 1788-1800.
116. Powell JS, Josephson NC, Quon D, et al Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012; 119(13):3031-3037.
117. Peters RT, Toby G, Lu Q., et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost. 2013; 11(1):132-141.
118. Zollner SB, Raquet E, Müller-Cohrs J, et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res. 2013; 132(2):280-287.
119. Zollner S, Raquet E, Claar P., et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014; 134(1): 125-131.
120. Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res. 2013; 131(suppl 2):S2-S6.
121. Mahlangu J, Kuliczkowski K, Karim F.A., et al; AFFINITY Investigators. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016; 128(5):630-637.
122. Liu T, Chhabra ES, Kulman J, et al Prolonged efficacy in hemophilia A mouse bleeding models of a recombinant FVIII-XTEND/D'D3 heterodimer with four-fold extended half-life in circulation. Haemophilia. 2014; 20(s3):76.
123. Shima M, Hanabusa H, Taki M., et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016; 374(21):2044-2053.
124. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res. 2013; 30(7):1729-1734.
125. Tiede A, Brand B, Fischer R., et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013; 11(4): 670-678.
126. Konkle BA, Stasyshyn O, Chowdary P., et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015; 126(9): 1078-1085.
127. Coyle TE, Reding MT, Lin J.C., Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014; 12(4):488-496.
128. Lenting PJ, van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007; 5(7): 1353-1360.
129. Dimitrov JD, Christophe OD, Kang J, et al Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor. Biochemistry. 2012; 51(20):4108-4116.